Trisomy 21 consistently activates the interferon response

Although it is clear that trisomy 21 causes Down syndrome, the molecular events acting downstream of the trisomy remain ill defined. Using complementary genomics analyses, we identified the interferon pathway as the major signaling cascade consistently activated by trisomy 21 in human cells. Transcriptome analysis revealed that trisomy 21 activates the interferon transcriptional response in fibroblast and lymphoblastoid cell lines, as well as circulating monocytes and T cells. Trisomy 21 cells show increased induction of interferon-stimulated genes and decreased expression of ribosomal proteins and translation factors. An shRNA screen determined that the interferon-activated kinases JAK1 and TYK2 suppress proliferation of trisomy 21 fibroblasts, and this defect is rescued by pharmacological JAK inhibition. Therefore, we propose that interferon activation, likely via increased gene dosage of the four interferon receptors encoded on chromosome 21, contributes to many of the clinical impacts of trisomy 21, and that interferon antagonists could have therapeutic benefits. DOI: http://dx.doi.org/10.7554/eLife.16220.001

[1]  Jørgen H Olsen,et al.  Low risk of solid tumors in persons with Down syndrome , 2016, Genetics in Medicine.

[2]  D. Steensma,et al.  A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) , 2016, Clinical Cancer Research.

[3]  Jianping Wang,et al.  A direct cross-talk between interferon-γ and sonic hedgehog signaling that leads to the proliferation of neuronal precursor cells , 2010, Brain, Behavior, and Immunity.

[4]  G. Smyth,et al.  Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks , 2014, BMC Genomics.

[5]  B. Jallal,et al.  Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus , 2010, Arthritis research & therapy.

[6]  M. Figueroa,et al.  Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. , 2013, Blood.

[7]  Claudia Angelini,et al.  AnaLysis of Expression on human chromosome 21, ALE-HSA21: a pilot integrated web resource , 2014, Database J. Biol. Databases Curation.

[8]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[9]  Sannah Zoffmann,et al.  White-to-brown metabolic conversion of human adipocytes by JAK inhibition , 2014, Nature Cell Biology.

[10]  A. Tefferi,et al.  Long-term outcome of treatment with ruxolitinib in myelofibrosis. , 2011, The New England journal of medicine.

[11]  C. Schindler,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. , 1993, Nature.

[12]  S. Catuara-Solarz,et al.  A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials , 2015, Front. Psychol..

[13]  Dean Nizetic,et al.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome , 2015, Nature Reviews Neuroscience.

[14]  C. Epstein,et al.  Human Chromosome 21 Dosage: Effect on the Expression of the Interferon Induced Antiviral State , 1974, Science.

[15]  P. Cheah,et al.  Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain , 2016, Neural plasticity.

[16]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[17]  M. L. Montesinos,et al.  The Akt-mTOR pathway in Down's syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits. , 2014, CNS & neurological disorders drug targets.

[18]  J. Lawrence,et al.  Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity to human interferon , 1978, Journal of virology.

[19]  J. Treuner,et al.  Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication , 1999, European Journal of Pediatrics.

[20]  D. Spaner,et al.  Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial , 2016, Haematologica.

[21]  Borut Peterlin,et al.  Expression Signature as a Biomarker for Prenatal Diagnosis of Trisomy 21 , 2013, PloS one.

[22]  Stephen A. Williams,et al.  Validation of a blood protein signature for non-small cell lung cancer , 2014, Clinical Proteomics.

[23]  S. Izraeli,et al.  Haematopoietic development and leukaemia in Down syndrome , 2014, British journal of haematology.

[24]  T. Johnson,et al.  INHIBITION OF PROTEIN SYNTHESIS IN NONINFECTED L CELLS BY PARTIALLY PURIFIED INTERFERON PREPARATIONS , 1968, The Journal of cell biology.

[25]  J. Crispino,et al.  Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. , 2012, The Journal of clinical investigation.

[26]  M. Genovese,et al.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate , 2014, Annals of the rheumatic diseases.

[27]  Henry W. Long,et al.  HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia , 2013, Cell.

[28]  M. Wichers,et al.  The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. , 2004, Journal of psychiatry & neuroscience : JPN.

[29]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[30]  L. Maroun Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. , 1995, Teratology.

[31]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[32]  P. Brown,et al.  Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells , 2010, PloS one.

[33]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[34]  Pei Wang,et al.  Effects of small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis , 2008, Cell biology international.

[35]  Alan G Hinnebusch,et al.  The scanning mechanism of eukaryotic translation initiation. , 2014, Annual review of biochemistry.

[36]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[37]  N. Nowak,et al.  Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. , 2007, Human molecular genetics.

[38]  J. Dambrosia,et al.  Interferons and cerebral palsy. , 1999, The Journal of pediatrics.

[39]  Sarah L McGlasson,et al.  Type I interferon dysregulation and neurological disease , 2015, Nature Reviews Neurology.

[40]  M. Maes,et al.  IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity , 2005, Molecular Psychiatry.

[41]  Christopher C. Porter,et al.  ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53 , 2012, Nature chemical biology.

[42]  H. Drexler,et al.  Detection of mycoplasma in leukemia–lymphoma cell lines using polymerase chain reaction , 2002, Leukemia.

[43]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[44]  D. Linden,et al.  Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model , 2013, Science Translational Medicine.

[45]  D. Walsh,et al.  Tinkering with translation: protein synthesis in virus-infected cells. , 2013, Cold Spring Harbor perspectives in biology.

[46]  D. Butterfield,et al.  mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy , 2015, Neurobiology of Disease.

[47]  R. Carlson,et al.  Solid malignancies in individuals with Down syndrome: a case presentation and literature review. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[48]  J. Mulliken,et al.  Spastic Diplegia as a Complication of Interferon Alfa‐2a Treatment of Hemangiomas of Infancy , 1998, The Journal of pediatrics.

[49]  G. Plosker Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis , 2015, Drugs.

[50]  A. Christiano,et al.  Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib , 2015, EBioMedicine.

[51]  Takashi Nakamura,et al.  Influences of interferon-gamma on cell proliferation and interleukin-6 production in Down syndrome derived fibroblasts. , 2009, Archives of oral biology.

[52]  Matthew J. Stephens,et al.  Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral Therapy , 2007, Journal of Virology.

[53]  C. Dang,et al.  Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Dhanasekaran,et al.  Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain , 2013, Human molecular genetics.

[55]  M Schwab,et al.  N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.

[56]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[57]  W. Mobley,et al.  Questioned validity of Gene Expression Dysregulated Domains in Down's Syndrome , 2015, F1000Research.

[58]  M. V. Capela,et al.  Expression of interferon-γ, interferon-α and related genes in individuals with Down syndrome and periodontitis. , 2012, Cytokine.

[59]  Christopher C. Ebmeier,et al.  CDK8 is a positive regulator of transcriptional elongation within the serum response network , 2010, Nature Structural &Molecular Biology.

[60]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[61]  K. McKeage Ruxolitinib: A Review in Polycythaemia Vera , 2015, Drugs.

[62]  L. Maroun Interferon-mediated effect on ribosomal RNA metabolism. , 1978, Biochimica et biophysica acta.

[63]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[64]  A. Ciccodicola,et al.  Massive-Scale RNA-Seq Analysis of Non Ribosomal Transcriptome in Human Trisomy 21 , 2011, PloS one.

[65]  Stylianos E. Antonarakis,et al.  Domains of genome-wide gene expression dysregulation in Down’s syndrome , 2014, Nature.

[66]  Lars-Gunnar Larsson,et al.  c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription , 2005, Nature Cell Biology.

[67]  Y. Crow,et al.  Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.

[68]  N. Morgan,et al.  Immunopathology of the human pancreas in type-I diabetes , 2011, Seminars in Immunopathology.

[69]  Jing Wang,et al.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 , 2013, Nucleic Acids Res..

[70]  Hyungwon Choi,et al.  QPROT: Statistical method for testing differential expression using protein-level intensity data in label-free quantitative proteomics. , 2015, Journal of proteomics.

[71]  B. Teh,et al.  Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. , 2003, Cancer research.

[72]  V. Srikanth,et al.  Risk of Major Cardiovascular Events in People with Down Syndrome , 2015, PloS one.

[73]  G. Stark,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.

[74]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[75]  J. Darnell,et al.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions , 1994, Cell.

[76]  Charles M. Rice,et al.  Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response , 2015, Nature.

[77]  J. Crispino,et al.  AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL , 2013, Leukemia.

[78]  Milton W. Taylor,et al.  Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC) , 2012, Journal of Translational Medicine.

[79]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[80]  P. Chambon,et al.  Tripartite Motif 24 (Trim24/Tif1α) Tumor Suppressor Protein Is a Novel Negative Regulator of Interferon (IFN)/Signal Transducers and Activators of Transcription (STAT) Signaling Pathway Acting through Retinoic Acid Receptor α (Rarα) Inhibition* , 2011, The Journal of Biological Chemistry.

[81]  B. Frier,et al.  Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[82]  P. Scherle,et al.  The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers , 2014, Journal of clinical pharmacology.

[83]  Eric P. Hoffman,et al.  Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy , 2015, Proceedings of the National Academy of Sciences.

[84]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[85]  H. Petri,et al.  Morbidity and medication in a large population of individuals with Down syndrome compared to the general population , 2016, Developmental medicine and child neurology.

[86]  E. Aronica,et al.  mTOR Hyperactivation in down syndrome hippocampus appears early during development. , 2014, Journal of neuropathology and experimental neurology.

[87]  T. Heffernan,et al.  Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.